InventivaGiven that IVA is on a very similiar pathway with their NASH phase III trial as TH, I thought the following link to a report on IVA would be of interest to some here:
https://lifesci.bluematrix.com/links2/pdf/e23413b5-8899-49f7-b5ac-06a2424baba4
IVA currently has a market cap of US$526 million, almost twice what TH's market cap is and I believe all IVA has is its NASH phase III opportunity.
IVA has about two times as much cash on the balance sheet than does TH and strong phase II trial data supporting their phase III. But the PPAR class of drugs has had safety issues and that is clearly a risk for IVA's phase III. None of the phase III NASH trials are completely wart free. Still the analyst inn this case gives IVA's phase III trial a 70% chance of success, which is in stark contrast to Mackie's 10% chance of success for TH.